Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Topical benzyl benzoate–based treatment reduced Demodex in patients with rosacea

Publish date:: October 25, 2019

Key clinical point: A benzoyl benzoate (BB) cream was effective in clearing or reducing demodicosis, with improvements in rosacea symptoms.

Major finding: In the retrospective observational study, all concentrations of BB (12% once daily, 12% twice daily, and 20%024% once daily) effected similar rates of clearance, with normalization of Demodex densities in 35% and symptoms resolved in 46%.

Study details: A retrospective observational study of 394 patients with rosacea or demodicosis, treated for a mean of 2.7 months with a BB cream.

Disclosures: Dr. Forton disclosed that he occasionally works as a consultant for Galderma; the second author had no disclosures. The study had no funding source.

Citation:

Forton FMN et al. J Eur Acad Dermatol Venereol. 2019 Sep 7. doi: 10.1111/jdv.15938.

This Week's Must Reads

Osteoporosis prevalence in PsA similar to general population,

Swedish registry study finds atopic dermatitis significantly associated with autoimmune diseases,

More severe AD correlates with worse sleep health and attention problems in children,

Shortcomings identified in study of acne videos on TikTok,

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Must Reads in Rosacea

Study results support screening rosacea patients for cardiometabolic disease,

Review finds evidence for beta-blockers for some rosacea symptoms,

New rosacea clinical management guidelines focus on symptomatology,

Energy-based therapy plus oxymetazoline proves safe for rosacea,

Topical benzyl benzoate–based treatment reduced Demodex in patients with rosacea,